Expanded access for Zolgensma following final NICE guidance
The National Institute for Health and Care Excellence (NICE) has published its final guidance on Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma.
July 12, 2021
by pharmatimes
Zolgensma shows promise in presymptomatic SMA patients
Novartis’ gene therapy Zolgensma has shown benefit for presymptomatic spinal muscular atrophy (SMA) patients, according to new data presented at the annual European Academy for Neurology (EAN) virtual congress.
June 22, 2021
by pharmatimes
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland
The Scottish Medicines Consortium (SMC) has accepted Novartis Gene Therapies' Zolgensma and Genentech’s Rozlytrek for use by NHS Scotland as part of its March 2021 decisions.
March 10, 2021
by pharmatimes
NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma
NHS England and Novartis Gene Therapies have signed a ‘landmark’ agreement that will make Zolgensma available for patients on the NHS.
March 8, 2021
by pharmatimes
Financial Report: Novartis
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
November 6, 2020
by contractpharma
REGENXBIO Achieves $80M Novartis Milestone
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.
October 29, 2020
by contractpharma
Novartis faces delay in expansion of SMA drug Zolgensma indication
Novartis is facing a delay in expansion of indication for its spinal muscular atrophy (SMA) drug Zolgensma (onasemnogene abeparvovec).
September 27, 2020
by pharmaceutical-technology
AveXis Receives EC Approval, Activates “Day One” Access Spinal Muscular Atrophy Gene Therapy
AveXis, a Novartis company, announced the European Commission (EC) granted conditional approval for Zolgensma® (onasemnogene abeparvovec) ...
May 26, 2020
by americanpharmaceuticalreview
Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy
Novartis company AveXis has secured conditional approval from the European Commission (EC) for its Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
May 21, 2020
by pharmaceutical-business-review
Novartis’ AveXis gets EC conditional approval for Zolgensma
Novartis subsidiary AveXis has received conditional approval from the European Commission (EC) for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
May 20, 2020
by pharmaceutical-technology
Study suggests Zolgensma will generate $2.5bn of global sales by 2025
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
April 1, 2020
by europeanpharmaceuticalreview
Novartis gets positive CHMP opinion for Zolgensma and Cosentyx
Novartis has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for Zolgensma in spinal muscular atrophy (SMA), and Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).
March 31, 2020
by pharmaceutical-technology